NICE
Grant NICE greater trial data access – report
May 29, 2013Research and Development, Sales and Marketing Goldacre, NICE, transparency, trials
A new report by the National Audit Office says NICE should be given greater powers to access clinical trial data. …
NICE chairman joins biotech Board
May 17, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Intra-Cellular Therapies, NICE, Rawlins
Biotech firm Intra-Cellular Therapies has appointed former NICE chairman Professor Sir Michael Rawlins to its Board of directors. Rawlins was …
Government ‘joins-up’ system
May 15, 2013Sales and Marketing NHS, NICE, government, king's fund
The government has launched its plans to create ‘a truly joined-up system’ for the provision of health and social care …
NICE to assess drug value
March 22, 2013Sales and Marketing EMIG, NHS, NICE, VBP
NICE will be responsible for assessing the full value of medicines – taking into account their benefit to patients and …
Eliquis approved by NICE
February 28, 2013Sales and Marketing BMS, Eliquis, NICE, Pfizer
In a move which will cheer Bristol-Myers Squibb and Pfizer, NICE has recommended oral blood-thinner Eliquis for use on the …
NICE rejects Jakavi
February 13, 2013Sales and Marketing Jakavi, NICE
NICE has today issued draft guidance saying it does not recommend Novartis’ Jakavi for patients with myelofibrosis, a rare blood …
NICE rejects Forxiga
February 1, 2013Sales and Marketing AstraZeneca, BMS, Forxiga, NICE, diabetes
NICE has given the thumbs-down to AstraZeneca and Bristol-Myers Squibb’s first-in-class type II diabetes treatment Forxiga. The drug was approved …
NICE hits back at ‘limited’ EC study
January 28, 2013Sales and Marketing ABPI, EC, NHS, NICE, QALY, Whitehead
NICE has delivered a robust defence of the methods by which it arrives at a judgment on the value of …
MPs: ‘get on with VBP’
January 18, 2013Medical Communications, Sales and Marketing NHS, NICE, PPRS, VBP
An influential group of MPs has hit out at inactivity over moves towards value-based pricing (VBP), saying that the issue …
The price of innovation
January 16, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, NHS, NICE, Rose, VBP
One of the strange paradoxes of our industry is that we have a very large number of new medicines in …
NICE consults on tamoxifen
January 15, 2013Sales and Marketing Cancer, Evista, NICE, lilly, tamoxifen
Patient groups have welcomed NICE’s new draft guideline recommending the use of preventive treatments in women who have a family …
New price and data changes NICE view on Lucentis
January 4, 2013Sales and Marketing Bayer, Eylea, Lucentis, NICE, Novartis
A new lower price and new data analysis has persuaded NICE to recommend Lucentis for patients with diabetic macular oedema …
NICE publishes formulary guidance
December 19, 2012Sales and Marketing ABPI, NHS, NICE, formularies, formulary
NICE has published its first guidance on good practice for those involved in working out what medicines should be made …
David Haslam confirmed as NICE chair
December 18, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Haslam, Hunt, NICE
David Haslam has been confirmed as chair of the National Institute for Health and Clinical Excellence. Professor Haslam is currently …
‘Open door’ for pharma
December 6, 2012Sales and Marketing CCGs, NHS, NICE, Pharmafocus, Prescriber, UK
The NHS’s new clinical commissioning groups (CCGs) will be more welcoming to approaches from pharma than the old PCTs were, …
